# NCT02496208 (NCT02496208)

> Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02496208
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Sarcomatoid Urothelial Carcinoma; Kidney Medullary Carcinoma; Malignant Genitourinary System Neoplasm; Malignant Solid Neoplasm; Penile Carcinoma; Penile Squamous Cell Carcinoma; Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma
- Interventions: Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Enrollment: 152
- Primary outcome: Recommended phase II dose (Phase I)
- Primary outcome: Incidence of adverse events (Phase I)

## Indexed commentary on NCT02496208 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02496208